Phase IV, Open, Multicentre, Single-arm Study to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression.
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms GENIS
- 01 Oct 2018 Planned End Date changed from 23 Feb 2020 to 31 May 2020.
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2018 New trial record